Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance

Shawna Mae Hengel; Euan Murray; Simon Langdon; Larry Hayward; Jean O'Donoghue; Alexandre Panchaud; Ted Hupp; David R Goodlett

doi:10.1021/pr2004117

Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance

Shawna Mae Hengel, Euan Murray, Simon Langdon, Larry Hayward, Jean O'Donoghue, Alexandre Panchaud, Ted Hupp, David R Goodlett

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

A label-free quantitative variation of the recently developed data-independent shotgun proteomic method precursor acquisition independent from ion count (PAcIFIC) was used to identify novel proteins implicated in cancer progression and resistance. Specifically, this screen identified the pro-metastatic protein anterior gradient 2 (AGR2) as significantly up-regulated in tamoxifen-treated cells. Highlighting the need for direct proteome profiling methods like PAcIFIC, neither data-dependent gas-phase fractionation nor a transcriptomic screen detected AGR2 protein/transcript at significantly up-regulated levels. Further cell-based experiments using human cancer cell lines and in vivo xenografts confirmed the PAcIFIC hypothesis that AGR2 is up-regulated in MCF-7 cells post tamoxifen treatment and that it is implicated in drug resistance mediation.

Original language	English
Pages (from-to)	4567-78
Number of pages	12
Journal	Journal Of Proteome Research
Volume	10
Issue number	10
DOIs	https://doi.org/10.1021/pr2004117
Publication status	Published - 2011

Access to Document

10.1021/pr2004117

Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance
NIH public access author manuscript. Europe PMC open access link
Accepted author manuscript, 1.18 MB

http://pubs.acs.org/doi/abs/10.1021/pr2004117

Cite this

@article{c70d260db25542fd9d12234bc03bb2ce,

title = "Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance",

abstract = "A label-free quantitative variation of the recently developed data-independent shotgun proteomic method precursor acquisition independent from ion count (PAcIFIC) was used to identify novel proteins implicated in cancer progression and resistance. Specifically, this screen identified the pro-metastatic protein anterior gradient 2 (AGR2) as significantly up-regulated in tamoxifen-treated cells. Highlighting the need for direct proteome profiling methods like PAcIFIC, neither data-dependent gas-phase fractionation nor a transcriptomic screen detected AGR2 protein/transcript at significantly up-regulated levels. Further cell-based experiments using human cancer cell lines and in vivo xenografts confirmed the PAcIFIC hypothesis that AGR2 is up-regulated in MCF-7 cells post tamoxifen treatment and that it is implicated in drug resistance mediation.",

author = "Hengel, {Shawna Mae} and Euan Murray and Simon Langdon and Larry Hayward and Jean O'Donoghue and Alexandre Panchaud and Ted Hupp and Goodlett, {David R}",

year = "2011",

doi = "10.1021/pr2004117",

language = "English",

volume = "10",

pages = "4567--78",

journal = "Journal Of Proteome Research",

publisher = "American Chemical Society",

number = "10",

}

TY - JOUR

T1 - Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance

AU - Hengel, Shawna Mae

AU - Murray, Euan

AU - Langdon, Simon

AU - Hayward, Larry

AU - O'Donoghue, Jean

AU - Panchaud, Alexandre

AU - Hupp, Ted

AU - Goodlett, David R

PY - 2011

Y1 - 2011

N2 - A label-free quantitative variation of the recently developed data-independent shotgun proteomic method precursor acquisition independent from ion count (PAcIFIC) was used to identify novel proteins implicated in cancer progression and resistance. Specifically, this screen identified the pro-metastatic protein anterior gradient 2 (AGR2) as significantly up-regulated in tamoxifen-treated cells. Highlighting the need for direct proteome profiling methods like PAcIFIC, neither data-dependent gas-phase fractionation nor a transcriptomic screen detected AGR2 protein/transcript at significantly up-regulated levels. Further cell-based experiments using human cancer cell lines and in vivo xenografts confirmed the PAcIFIC hypothesis that AGR2 is up-regulated in MCF-7 cells post tamoxifen treatment and that it is implicated in drug resistance mediation.

AB - A label-free quantitative variation of the recently developed data-independent shotgun proteomic method precursor acquisition independent from ion count (PAcIFIC) was used to identify novel proteins implicated in cancer progression and resistance. Specifically, this screen identified the pro-metastatic protein anterior gradient 2 (AGR2) as significantly up-regulated in tamoxifen-treated cells. Highlighting the need for direct proteome profiling methods like PAcIFIC, neither data-dependent gas-phase fractionation nor a transcriptomic screen detected AGR2 protein/transcript at significantly up-regulated levels. Further cell-based experiments using human cancer cell lines and in vivo xenografts confirmed the PAcIFIC hypothesis that AGR2 is up-regulated in MCF-7 cells post tamoxifen treatment and that it is implicated in drug resistance mediation.

UR - http://www.scopus.com/inward/record.url?scp=80053909031&partnerID=8YFLogxK

U2 - 10.1021/pr2004117

DO - 10.1021/pr2004117

M3 - Article

C2 - 21936522

VL - 10

SP - 4567

EP - 4578

JO - Journal Of Proteome Research

JF - Journal Of Proteome Research

IS - 10

ER -

Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance

Abstract / Description of output

Access to Document

Other files and links

Fingerprint

Cite this